Optimizing CAR T-cell therapy to tackle solid tumors
Medical Xpress
February 16, 2026
In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite prostaglandin E2 can block T cells—the killer cells of the immune system—in the vicinity of a tumor, such that they do not attack cancer cells. This is one of the reasons why therapeutic CAR T cells have lacked success against solid tumors such as bowel or pancreatic cancer.
Verticals
healthmedical
Originally published on Medical Xpress on 2/16/2026